Therapeutic potential of Galectin‐9 in human disease
Citations Over TimeTop 10% of 2011 papers
Abstract
In recent years, an important role has emerged for the glycan-binding protein Galectin-9 (Gal-9) in health and disease. In normal physiology, Gal-9 seems to be a pivotal modulator of T-cell immunity by inducing apoptosis in specific T-cell subpopulations. Because these T-cell populations are associated with autoimmunity, inflammatory disease, and graft rejection, it was postulated that application of exogenous Gal-9 may limit pathogenic T-cell activity. Indeed, treatment with recombinant Gal-9 ameliorates disease activity in various preclinical models of autoimmunity and allograft graft rejection. In many solid cancers, the loss of Gal-9 expression is closely associated with metastatic progression. In line with this observation, treatment with recombinant Gal-9 prevents metastatic spread in various preclinical cancer models. In addition, various hematological malignancies are sensitive to apoptotic elimination by recombinant Gal-9. Here, we review the biology and physiological role of this versatile lectin and discuss the therapeutic potential of Gal-9 in various diseases, including autoimmunity, asthma, infection, and cancer.
Related Papers
- → Sialylation of β1 Integrins Blocks Cell Adhesion to Galectin-3 and Protects Cells against Galectin-3-induced Apoptosis(2008)131 cited
- → Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?(2022)14 cited
- → The Levels of Expression of Galectin‐3, But Not of Galectin‐1 and Galectin‐8, Correlate With Apoptosis in Human Cholesteatomas(2001)34 cited
- → Galectin-1-expression and effect on proliferation and migration of glioma cells(2006)
- → Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis(2020)